After FDA approval of RP1 plus nivolumab, melanoma specialists now look toward preparing for clinical use and consider the future of intratumoral therapy trials.
David Savage, MD, PhD
Advertisement
Articles by David Savage, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Savolitinib Plus Osimertinib Improves PFS, OS in MET-Driven NSCLC
2
FDA Grants Type C Meeting for OST-HER2 OS Data in Osteosarcoma
3
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
4
VA Study Finds Potential OS Benefit for Enzalutamide in Older mCSPC Patients
5